BioMarin Pharmaceutical Inc. Stock News

Although US stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto

Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 9 1 0

Over the past 3 months, 10 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. These analysts are typically employed by large Wall Street banks and tasked with unders

Upgrades Morgan Stanley upgraded the previous rating for Pure Storage Inc (NYSE:PSTG) from Equal-Weight to Overweight. In the second quarter, Pure Storage showed an EPS of $0.32, compared to $0.14 fr

Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to $3

Investors were expecting better top-line numbers from the company's earnings report.

Investors were expecting better top-line numbers from the company's earnings report.

BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.

BioMarin (BMRN) delivered earnings and revenue surprises of 21.62% and 1.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN ) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET Company Participants Traci McCarty - VP, IR J.J. Bienaime - Chairman & CEO Jeffrey Ajer - EVP

BioMarin (BMRN) delivered earnings and revenue surprises of 21.62% and 1.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.